CEO Richard Kirk talks about the development and successes of Noctura 400. With an in depth understanding of the diabetic retinopathy disease pathway and the patients that Noctura 400 has helped treat Richard warmly recounts their journeys, but also reflects on the potential of Noctura 400 not just in the UK, but around the world.